Restart Life Sciences (NMLSF) Stock Statistics & Valuation Metrics
Total Valuation
Restart Life Sciences has a market cap or net worth of $3.57M. The enterprise value is $4.75M.
- Market Cap
- $3.57M
- Enterprise Value
- $4.75M
Share Statistics
Restart Life Sciences has 62,506,542 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 62,506,542
- Owned by Insiders
- 13.94%
- Owned by Institutions
- ―
Financial Efficiency
Restart Life Sciences’s return on equity (ROE) is -1.08 and return on invested capital (ROIC) is -87.79%.
- Return on Equity (ROE)
- -1.08
- Return on Assets (ROA)
- -0.79
- Return on Invested Capital (ROIC)
- -87.79%
- Return on Capital Employed (ROCE)
- -1.05
- Revenue Per Employee
- 0
- Profits Per Employee
- -463.51K
- Employee Count
- 3
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Restart Life Sciences is -1.96. Restart Life Sciences’s PEG ratio is 0.23.
- PE Ratio
- -1.96
- PS Ratio
- 10.74
- PB Ratio
- 3.67
- Price to FCF
- -5.08
- Price to Operating Cash Flow
- -4.94
- PEG Ratio
- 0.23
Income Statement
In the last 12 months, Restart Life Sciences had revenue of 0 and earned -1.39M in profits. Earnings per share was -0.04.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -1.35M
- Pretax Income
- -1.39M
- Net Income
- -1.39M
- EBITDA
- -1.34M
- Earnings Per Share (EPS)
- -0.04
Cash Flow
In the last 12 months, operating cash flow was -906.33K and capital expenditures 0, giving a free cash flow of -906.33K billion.
- Operating Cash Flow
- -906.33K
- Free Cash Flow
- -906.33K
- Free Cash Flow per Share
- -0.02
Dividends & Yields
Restart Life Sciences pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -19.68%
- Earnings Yield
- -35.21%
Stock Price Statistics
- Beta
- 4.04
- 52-Week Price Change
- -80.00%
- 50-Day Moving Average
- 0.04
- 200-Day Moving Average
- 0.06
- Relative Strength Index (RSI)
- 40.10
- Average Volume (3m)
- 1,949
Important Dates
Restart Life Sciences upcoming earnings date is Dec 02, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 27, 2026
- Next Earnings Date
- Dec 02, 2026
- Ex-Dividend Date
- ―
Financial Position
Restart Life Sciences as a current ratio of 3.67, with Debt / Equity ratio of 19.06%
- Current Ratio
- 3.67
- Quick Ratio
- 3.67
- Debt to Market Cap
- 0.06
- Net Debt to EBITDA
- 1.01
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Restart Life Sciences has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Restart Life Sciences EV to EBITDA ratio is -2.79, with an EV/FCF ratio of -4.79.
- EV to Sales
- 10.12
- EV to EBITDA
- -2.79
- EV to Free Cash Flow
- -4.79
- EV to Operating Cash Flow
- -4.79
Balance Sheet
Restart Life Sciences has $762.36K in cash and marketable securities with $348.35K in debt, giving a net cash position of $414.02K billion.
- Cash & Marketable Securities
- $762.36K
- Total Debt
- $348.35K
- Net Cash
- $414.02K
- Net Cash Per Share
- $0.01
- Tangible Book Value Per Share
- $0.01
Margins
Gross margin is -175.04%, with operating margin of -365.86%, and net profit margin of -367.41%.
- Gross Margin
- -175.04%
- Operating Margin
- -365.86%
- Pretax Margin
- -367.41%
- Net Profit Margin
- -367.41%
- EBITDA Margin
- -362.82%
- EBIT Margin
- -365.86%
Analyst Forecast
The average price target for Restart Life Sciences is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- -656.67%
